Inclusion Criteria:

- Confirmed diagnosis of a solid tumor malignancy, not to include lymphoma, that has
failed standard therapy or for which no standard therapy is available

- Adequate organ function as determined ≤ 7 days prior to starting study medication

- Eastern Cooperative Oncology Group performance status 0 to 2

- At least 3 weeks and recovery from effects of major prior surgery or other therapy,
including chemotherapy, radiation therapy, immunotherapy, or cytokine, biologic, or
vaccine therapy

Exclusion criteria

- Other significant medical disease

- History or presence of leptomeningeal disease

- Coexisting condition that would require the subject to continue therapy during the
treatment phase of the study with a drug known to alter renal function

- Pregnant or lactating